Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Thermo Fisher launches NGS hybrid capture assay

June 2025—Thermo Fisher Scientific has introduced the One Lambda HybriType HLA Plus Typing Flex kit, a next-generation sequencing hybrid capture assay featuring a probe-based design that optimizes read balance and uniformity, potentially mitigating allele dropout. The assay is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen class I and II genotyping analysis across various sample types, including whole blood and buccal swabs. It has a turnaround time of less than 5.5 hours, and the hands-on time is less than 2.5 hours. Data for the assay are analyzed using the company’s Type­Stream Visual NGS analysis software. The kit is for research use only.

Dr. Jonathan Epstein joins Advanced Uropathology

June 2025—Advanced Uropathology, a division of Integrated Medical Professionals, announced that urologic pathologist Jonathan Epstein, MD, has joined its team. Physicians, hospitals, and laboratories can now refer specimens directly to Dr. Epstein, who will provide second opinions and expert interpretations of complex urologic pathology cases.

Thermo Fisher launches centrifuges with GreenCool technology

June 2025—Thermo Fisher Scientific introduced new lines of floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union and U.S. Environmental Protection Agency fluorinated gas regulations. The Thermo Scientific Cryofuge, Bios, and Lynx centrifuges feature the company’s GreenCool technology, a next-generation natural refrigerant cooling system with a global warming potential of 1. Each model provides a reduction in energy consumption of up to 15 percent when compared with previous models.

IDT introduces xGen hybridization, wash kit v3

June 2025—Integrated DNA Technologies unveiled its xGen Hybridization and Wash version 3 kit. The kit features a high-throughput workflow that eliminates heated buffers and reduces hands-on time by 20 percent. The one-hour hybridization step delivers high-quality results and enables users to get from sample to sequencer in one day. The kit supports library inputs as low as 100 ng and pairs with xGen predesigned or custom Hyb panels and xGen Blocking Oligos.

Qiagen gets clearance for second QIAstat-Dx mini GI panel

June 2025—Qiagen announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. The panel focuses on bacterial infections covering Campylobacter, Salmonella, Shiga-like toxin-producing E. coli, Shigella, and Yersinia enterocolitica. It is designed to complement the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers Campylobacter, Salmonella, STEC, Shigella, and norovirus. The panel runs on the QIAstat-Dx system and delivers results in about one hour with less than one minute of hands-on time.

Sysmex adds XQ-320 to its line of three-part diff analyzers

June 2025—Sysmex America announced the expansion of its three-part differential automated hematology analyzer line with the XQ-320 for CBC testing. The XQ-320 has a throughput of up to 70 samples per hour, provides results in less than 60 seconds, and is the company’s first three-part differential analyzer that includes BeyondCare Quality Monitor. The analyzer features 17 parameters including an absolute neutrophil count, optional manual discrimination within histograms for challenging samples, robust flagging, and a low aspiration volume of 16 μL. It requires minimal weekly maintenance and offers a quick shutdown and automatic wake-up function.

Techcyte, Aiforia collaborate to advance AI-powered DP

June 2025—Techcyte and Aiforia announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories. The partnership brings together Techcyte’s Fusion digital pathology platform and Aiforia’s AI-powered diagnostic algorithms, beginning with the Aiforia breast cancer suite. The companies say the partnership will continue to drive innovation in digital pathology, cancer diagnostics, and more with an expanding portfolio of AI applications.

Verichem electrolyte testing reference materials

May 2025—Verichem Laboratories offers liquid stable, multianalyte kits of clinical reference materials intended for the calibration verification of electrolyte assays. The materials are designed to be treated as patient samples for use with systems using flame photometer, direct and indirect ion-selective electrode, or standard enzymatic/colorimetric testing methods. The electrolyte standard kit contains the analytes chloride, ionized calcium, lithium, potassium, and sodium and features a 21-month stability claim; the ISE standard kit contains chloride, lithium, potassium, and sodium and offers an 18-month stability claim. Carbon dioxide assays are covered by the CO2 standard kit and the standalone, ultrahigh CO2 standard level F, which have a 15-month stability claim.

Vitro appoints Biocare Medical as exclusive U.S. distributor

May 2025—Vitro announced it has appointed Biocare Medical (Pacheco, Calif.) as the exclusive distributor of its NeoPath Pro automated staining instrument in the United States. NeoPath Pro is a high-throughput platform with a 42-slide capacity, supporting immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization. The instrument was launched at the USCAP annual meeting in Boston, March 22–27. Vitro is headquartered in Spain.

MARKETPLACE

TRENDING